nach oben

Drugs

Erschienen in:

01.11.2018 | AdisInsight Report

Pyrotinib: First Global Approval

verfasst von: Hannah A. Blair

Erschienen in: Drugs | Ausgabe 16/2018

Einloggen, um Zugang zu erhalten

Abstract

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.

Escriva-de-Romani S, Arumi M, Bellet M, et al. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018;39:80–8.CrossRef

Ponde N, Brandao M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20.CrossRef

Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51–61.CrossRef

De Leon J. China approves Hengrui breast cancer drug on phase II data; 2018. https://www.biocentury.com/bc-extra/company-news/2018-08-22/china-approves-hengrui-breast-cancer-drug-phase-ii-data. Accessed 25 Sep 2018.

Lovells H. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs; 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1. Accessed 3 Sept 2018.

State Food and Drug Administration. Pyrotinib maleate tablets: prescribing information; 2018. http://202.96.26.102. Accessed 25 Sep 2018.

Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105–12.CrossRef

Wang Y, Qin Z, Wang Q, et al. Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation [abstract no. e24281]. J Clin Oncol. 2018;36(Suppl 15).

Zhu Y, Li L, Zhang G, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1033–1034:117–27.CrossRef

10.

Xu B, Ma F, Ouyang Q, et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab. [abstract no. PD3-08 plus poster]. Cancer Res. 2017;78(Suppl 4).

11.

Ren S, Zhou C, Gao G, et al. Preliminary results of a phase II study about the efficacy and safety of pyrotinib in patients with HER2 mutant advanced NSCLC [abstract no. MA04.03]. J Thorac Oncol. 2017;12(Suppl 1):S359.

Titel: Pyrotinib: First Global Approval
verfasst von: Hannah A. Blair
Publikationsdatum: 01.11.2018
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 16/2018
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-018-0997-0

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 16/2018

Moxetumomab Pasudotox: First Global Approval

Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies

Medical Use of Cannabinoids

Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity

Dolutegravir/Rilpivirine: A Review in HIV-1 Infection

Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities